Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2019-09-13 Interim / Quarterly Rep…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma présente ses résultats financiers et l’avancée de son portefeuille au premier semestre 2019
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Innate Pharma for the first half of 2019. It includes detailed financial statements (consolidated income statement, balance sheet data), management's discussion and analysis of financial results, and updates on the company's clinical pipeline and corporate developments. It is not a mere announcement (RPA) as it contains substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2019
2019-09-13 English
Innate Pharma reports first half 2019 financial results and business update
Earnings Release Classification · 1% confidence The document is titled "INNATE PHARMA REPORTS FIRST HALF 2019 FINANCIAL RESULTS AND BUSINESS UPDATE" and explicitly states, "Innate Pharma SA... today reports its consolidated financial results for the first six months of 2019." It contains detailed financial highlights, comparative tables for the six-month period ended June 30, 2019, and a pipeline update. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it classifies as an Interim / Quarterly Report (IR). Although it mentions financial statements are attached, the document itself contains the core results and analysis, making it the report, not just an announcement of the report (RPA). H1 2019
2019-09-13 English
Innate Pharma présente ses résultats financiers et l’avancée de son portefeuille au premier semestre 2019
Earnings Release Classification · 1% confidence The document is titled "INNATE PHARMA PRÉSENTE SES RÉSULTATS FINANCIERS ET L'AVANCÉE DE SON PORTEFEUILLE AU PREMIER SEMESTRE 2019" and explicitly states, "Innate Pharma SA... annonce aujourd'hui ses résultats financiers consolidés pour le premier semestre 2019." It contains detailed financial tables summarizing performance for the first half of 2019 (H1 2019), including revenue, operating expenses, net income, and balance sheet items as of June 30, 2019. This content structure—a press release announcing detailed financial figures for a period shorter than a year—is characteristic of an Interim/Quarterly Report (IR). Although it is presented as a press release, the core content is the comprehensive financial summary for the half-year period, making 'IR' the most appropriate classification over a simple 'ER' (Earnings Release) or 'RPA' (Report Publication Announcement), especially given its length and detail. H1 2019
2019-09-13 French
Regulatory Filings 2019
Regulatory Filings
2019-09-05 English
Regulatory Filings 2019
Regulatory Filings
2019-08-30 English
Regulatory Filings 2019
Regulatory Filings
2019-08-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.